VRTX Kapitalisasi Akuntansi Vertex

Vertex Pharmaceuticals (VRTX) production capacities are operating at maximum efficiency thanks to modernized certified lines. Business growth relies on partnerships with genetic engineering laboratories to create innovative therapies. This price chart reflects the stability provided by the company's dominance in cystic fibrosis treatment, generating a steady cash flow of 20.37 driven by constant demand for life-saving medications.

Vertex Pharmaceuticals Incorporated (VRTX) - Nilai Buku Perusahaan saka 04.07.2022 nganti 28.10.2026

Rincian metrik keuangan lan pasar Vertex (VRTX)

- rega lan prakiraan konsensus rega:

Rega Vertex Corp|VRTX - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar Vertex Pharmaceuticals Incorporated|VRTX - Nilai Total Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Saham Vertex Pharmaceuticals|VRTX - Nilai Buku Perusahaan|Kapitalisasi Pasar marang Aset Bersih vrtx.com|VRTX - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Modal Vertex Pharmaceuticals|VRTX - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Vertex Pharmaceuticals Incorporated|VRTX - Gunggung utang perusahaan|Utang-utang marang aset resik Vertex Pharmaceuticals Incorporated

Ringkesan analitik perusahaan:VRTX - Vertex Corp

Professional capital evaluates the profile of Vertex Pharmaceuticals (VRTX) through the lens of tangible assets. The company's book capitalization trend reflects the net asset value minus all liabilities, stripping away market speculation. The growth of this metric confirms the accumulation of hard capital. For Vertex Pharmaceuticals (VRTX), this is based on the ownership of high-tech laboratories in the US. Monopoly status and patent protection make this asset fundamentally resilient.

Analisis pesaing Vertex Pharmaceuticals